The FY 2027 IPPS proposed rule matters less for the headline rate update and more because CMS is continuing to tighten the link between how a product is coded, how a case is grouped, and whether a hospital can recover enough cost to adopt it at scale.
The Centers for Medicare and Medicaid Services (CMS) is proposing a 2.4% Inpatient Prospective Payment System (IPPS) rate increase, with New Technology Add-on Payments (NTAP) expected to continue adding meaningful dollars in FY 2027.
This is not about the rate update
In a margin-constrained environment, however, this is not a blank check. Inpatient adoption still depends on whether a technology fits the Medicare Severity Diagnosis Related Grouping (MS-DRG), qualifies for incremental payment, and can be defended in a utilization review meeting as financially viable for the provider. This read is based on the proposed rule itself. (Centers for Medicare & Medicaid Services)
CMS is raising the payment-evidence bar
The most important commercial signal is that CMS is pressing manufacturers to satisfy a higher payment-evidence threshold. For many device and drug companies, the most significant change in this rule is that CMS is closing off the shortcut to supplemental payment, specifically the proposed repeal of the alternative pathway for certain NTAP and Outpatient Prospective Payment System (OPPS) pass-through applicants. Its NTAP guidance continues to center eligibility on the traditional three-part test of newness, DRG payment inadequacy, and substantial clinical improvement.
CMS also reinforces several longstanding elements of the NTAP infrastructure: a technology must be uniquely identifiable in hospital claims data to qualify, relying on Medicare Electronic Application Request Information System (MEARIS), public NTAP application summaries, the annual town hall, and the rulemaking record to operationalize these decisions.
In practical terms, this means the commercial task is not limited to generating excitement around innovation. The real work is building a payment dossier that can survive coding scrutiny, quantify underpayment under the base DRG, and translate clinical differentiation into hospital finance language early enough to shape the final rule.
DRG changes will reshape the adoption equation
The second key issue is the targeted rework of MS-DRG and related payment pathways. CMS is proposing a series of DRG changes across complex spinal fusion, cardiac device revision/replacement, periprosthetic joint infection, antibiotic-eluting bone void filler, and islet cell transplantation.
These updates will change which cases are recognized as unusually complex, which technologies can move a case into a better-paying grouping, and which products still rely on a temporary add-on rather than a durable coding-and-payment home.
For manufacturers and investors, the lesson is that hospitals do not adopt “technology” but a margin profile – and in a year when the base inpatient update is only 2.4%, that distinction is critical. Products that require hospitals to absorb a persistent negative spread will still face friction, even when the clinical story is strong. By contrast, technologies that improve the coded case picture, shorten length of stay, avert revision, or reduce post-acute spend will be far easier for providers to justify.
The evaluation lens is expanding beyond the index admission
The adjacent-site spillover deserves equal attention. CMS is proposing CJR-X as a mandatory nationwide model for lower-extremity joint replacements in both inpatient and hospital outpatient settings from October 1, 2027, while maintaining Long-Term Care Hospital (LTCH) payment updates and outlier policy for FY 2027.
The implication is that hospital buyers will increasingly evaluate drugs and medtech not only on index-admission reimbursement, but also on their effect across the episode and across sites of care. That is especially relevant for products positioned around revision avoidance, infection reduction, earlier mobilization, or lower downstream utilization in Skilled Nursing Facilities (SNF)/ LTCH settings.
The window to influence is short
Stakeholders should engage now because the rule was displayed on April 10, 2026, published on April 14, 2026, and comments are due by 5 p.m. EDT on June 9, 2026.
CMS has also already posted the NTAP machinery and application summaries that will shape the debate. Companies that act now will be able to “comment on policy” and also help write the reimbursement logic that ultimately guides provider behavior.
The way forward
We invite you to connect with us and our team at Simon-Kucher to map the relevant reimbursement policy stack to your product and channel strategy, stress-test your launch plans, and quantify cross-program exposure through scenario modeling so you can move from regulatory policy fluency to precision-driven actions at launch or in-market.
